{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%2C+Diffuse&page=48", "query": { "condition": "Lymphoma, Diffuse", "page": 48 }, "page_size": 10 }, "pagination": { "page": 48, "page_size": 10, "total_count": 1281, "total_pages": 129, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%2C+Diffuse&page=49&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%2C+Diffuse&page=47&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T18:54:28.049Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03311958", "title": "Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "Nivolumab, IV, 240 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2018-05-15", "completion_date": "2024-01-26", "has_results": false, "last_update_posted_date": "2025-04-06", "last_synced_at": "2026-10-15T18:54:28.049Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03311958" }, { "nct_id": "NCT07478848", "title": "Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Large B Cell Lymphoma", "Non Hodgkin Lymphoma (NHL)", "Diffuse Large B Cell Lymphoma (DLBCL)", "Diffuse Large B Cell Lymphoma Refractory", "Diffuse Large B Cell Lymphoma Relapsed" ], "interventions": [ { "name": "Vancomycin 125mg", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "CAR-T", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2026-05-29", "completion_date": "2029-01-01", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-15T18:54:28.049Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07478848" }, { "nct_id": "NCT00006379", "title": "Non-Ablative Allo HSCT For Hematologic Malignancies or SAA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases", "Precancerous/Nonmalignant Condition", "Small Intestine Cancer" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "graft-versus-tumor induction therapy", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 58, "start_date": "2000-06", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2011-12-08", "last_synced_at": "2026-10-15T18:54:28.049Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006379" }, { "nct_id": "NCT00002578", "title": "Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "cytarabine", "type": "DRUG" }, { "name": "gallium nitrate", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 35, "start_date": "1994-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-10-06", "last_synced_at": "2026-10-15T18:54:28.049Z", "location_count": 3, "location_summary": "Los Angeles, California • Buffalo, New York • The Bronx, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Buffalo", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002578" }, { "nct_id": "NCT00002520", "title": "Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Bladder Cancer", "Breast Cancer", "Colorectal Cancer", "Head and Neck Cancer", "Lung Cancer", "Lymphoma", "Prostate Cancer", "Testicular Germ Cell Tumor", "Tobacco Use Disorder", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "nicotine", "type": "DRUG" }, { "name": "Usual Care", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "19 Years to 120 Years" }, "enrollment_count": 434, "start_date": "1990-12-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2023-06-15", "last_synced_at": "2026-10-15T18:54:28.049Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002520" }, { "nct_id": "NCT05660967", "title": "Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Epcoritamab", "type": "BIOLOGICAL" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "75 Years", "maximum_age": null, "sex": "ALL", "summary": "75 Years and older" }, "enrollment_count": 111, "start_date": "2023-03-06", "completion_date": "2026-06-10", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-15T18:54:28.049Z", "location_count": 1, "location_summary": "Waukesha, Wisconsin", "locations": [ { "city": "Waukesha", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05660967" }, { "nct_id": "NCT00005964", "title": "Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 59, "start_date": "2000-05", "completion_date": "2006-03", "has_results": false, "last_update_posted_date": "2016-07-13", "last_synced_at": "2026-10-15T18:54:28.049Z", "location_count": 47, "location_summary": "Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005964" }, { "nct_id": "NCT00994500", "title": "Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Burkitt Lymphoma", "Childhood Central Nervous System Choriocarcinoma", "Childhood Central Nervous System Germ Cell Tumor", "Childhood Central Nervous System Germinoma", "Childhood Central Nervous System Mixed Germ Cell Tumor", "Childhood Central Nervous System Teratoma", "Childhood Central Nervous System Yolk Sac Tumor", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Medulloepithelioma", "Childhood Meningioma", "Childhood Mixed Glioma", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Childhood Oligodendroglioma", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Central Nervous System Embryonal Tumor", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Malignant Germ Cell Tumor", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Childhood Subependymal Giant Cell Astrocytoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma", "Recurrent Childhood Visual Pathway Glioma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 20, "start_date": "2009-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-02", "last_synced_at": "2026-10-15T18:54:28.049Z", "location_count": 6, "location_summary": "Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00994500" }, { "nct_id": "NCT01859819", "title": "Treatment for Advanced B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large Cell Lymphoma", "Burkitt's Lymphoma", "High Grade B-cell Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "IT Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New York Medical College", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "31 Years", "sex": "ALL", "summary": "3 Years to 31 Years" }, "enrollment_count": 45, "start_date": "2013-01", "completion_date": "2021-06", "has_results": false, "last_update_posted_date": "2022-10-25", "last_synced_at": "2026-10-15T18:54:28.049Z", "location_count": 5, "location_summary": "Buffalo, New York • Valhalla, New York • Charlotte, North Carolina + 2 more", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "Valhalla", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01859819" }, { "nct_id": "NCT00081809", "title": "A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Follicular", "Lymphoma, Small Lymphocytic" ], "interventions": [ { "name": "autologous human tumor-derived HSPPC-96", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agenus Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 35, "start_date": "2000-03", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2023-09-28", "last_synced_at": "2026-10-15T18:54:28.049Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00081809" } ] }